NeuroNEXT
NN110 – Enlite-PD: A Dose Selection Trial for Light Therapy for Impaired Sleep in Parkinson’s Disease
Enlite-PD is part of the Network for Excellence in Neuroscience Clinical Trials (NeuroNEXT), funded by the National Institute of Neurological Disorders and Stroke (NINDS). We are presently looking for individuals diagnosed with Parkinson’s disease with reported impaired sleep to participate in Enlite-PD, a randomized, placebo-controlled, dose-selection clinical trial.
A total of 144 subjects are expected to enroll across 25 sites. The primary objective of this study is to determine whether once- or twice-daily bright-white light therapy improves sleep in Parkinson’s disease.
Participation will include up to 5 research visits, including a screening visit over a 4-month period. Subjects will also be asked to complete a sleep and light therapy diary along with a number of questionnaires related to sleep, mood, and cognition.
For more information
Harini Sarva, MD
Principal Investigator
NewYork-Presbyterian/Weill Cornell Medical Center